[
  {
    "ts": null,
    "headline": "U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine",
    "summary": "The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against Covid-19 until after the election that Trump lost to Biden.",
    "url": "https://finnhub.io/api/news?id=4c74d63e9e28ed84b617bc22cfd15eb05acdd77538b9a4be580c9c17cbd687c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743028980,
      "headline": "U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine",
      "id": 133462123,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against Covid-19 until after the election that Trump lost to Biden.",
      "url": "https://finnhub.io/api/news?id=4c74d63e9e28ed84b617bc22cfd15eb05acdd77538b9a4be580c9c17cbd687c1"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Pfizer (PFE) Fell More Than Broader Market",
    "summary": "In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=cc9a02b22db2dca055ad69085cac2bc4facf8cd8bcc6e7c30381b589cccb74d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743025515,
      "headline": "Here's Why Pfizer (PFE) Fell More Than Broader Market",
      "id": 133462124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=cc9a02b22db2dca055ad69085cac2bc4facf8cd8bcc6e7c30381b589cccb74d2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Slips After Report on Vaccine Timing Probe",
    "summary": "Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion that the pharmaceutical giant delayed announcing a successful Covid-19 vaccine until after the 2020 election.",
    "url": "https://finnhub.io/api/news?id=9d14e370d2d8d9c5f4db9f01d59a76ad2b809ae6f452da16990dcede443b01fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743017153,
      "headline": "Pfizer Stock Slips After Report on Vaccine Timing Probe",
      "id": 133462126,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion that the pharmaceutical giant delayed announcing a successful Covid-19 vaccine until after the 2020 election.",
      "url": "https://finnhub.io/api/news?id=9d14e370d2d8d9c5f4db9f01d59a76ad2b809ae6f452da16990dcede443b01fc"
    }
  },
  {
    "ts": null,
    "headline": "Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns",
    "summary": "The Dividend Income Accelerator Portfolio focuses on financially healthy companies with strong balance sheets. Check out the recent additions to the portfolio.",
    "url": "https://finnhub.io/api/news?id=ce462cc0e5b7f820a511093e525334e1bca7d2a89963f65cc3b58e557cad4636",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743012000,
      "headline": "Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns",
      "id": 133460063,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072585234/image_1072585234.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The Dividend Income Accelerator Portfolio focuses on financially healthy companies with strong balance sheets. Check out the recent additions to the portfolio.",
      "url": "https://finnhub.io/api/news?id=ce462cc0e5b7f820a511093e525334e1bca7d2a89963f65cc3b58e557cad4636"
    }
  },
  {
    "ts": null,
    "headline": "US prosecutors probe tip about timing of Pfizer's COVID vaccine, WSJ reports",
    "summary": "Federal prosecutors in Manhattanare probing a claim by GSK that Pfizer delayedannouncing its COVID shot's success in 2020 until after thatyear's election, the Wall Street Journal reported, citing...",
    "url": "https://finnhub.io/api/news?id=e50eb07cd53192f744c33f4a852419436b0cdd6f802d731414972ba943bc09f1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743009747,
      "headline": "US prosecutors probe tip about timing of Pfizer's COVID vaccine, WSJ reports",
      "id": 133459825,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Federal prosecutors in Manhattanare probing a claim by GSK that Pfizer delayedannouncing its COVID shot's success in 2020 until after thatyear's election, the Wall Street Journal reported, citing...",
      "url": "https://finnhub.io/api/news?id=e50eb07cd53192f744c33f4a852419436b0cdd6f802d731414972ba943bc09f1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=ccb90e4a0c4f4555ff5c9f2cc1cf4f21682272769a4282c9b6c40bd6e382b27b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743006900,
      "headline": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
      "id": 133470819,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=ccb90e4a0c4f4555ff5c9f2cc1cf4f21682272769a4282c9b6c40bd6e382b27b"
    }
  },
  {
    "ts": null,
    "headline": "US Prosecutors Probe Tip About Timing Of Pfizer Vaccine - WSJ",
    "summary": "March 26 - * U.S. PROSECUTORS PROBE TIP ABOUT TIMING OF PFIZER VACCINE- WSJSource text: https://tinyurl.com/3smac3kwFurther company coverage: ...",
    "url": "https://finnhub.io/api/news?id=061765caf85defdbeb90099e10f425536b26118511de5b0ddec94bc1ac24cc38",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742996655,
      "headline": "US Prosecutors Probe Tip About Timing Of Pfizer Vaccine - WSJ",
      "id": 133458788,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "March 26 - * U.S. PROSECUTORS PROBE TIP ABOUT TIMING OF PFIZER VACCINE- WSJSource text: https://tinyurl.com/3smac3kwFurther company coverage: ...",
      "url": "https://finnhub.io/api/news?id=061765caf85defdbeb90099e10f425536b26118511de5b0ddec94bc1ac24cc38"
    }
  },
  {
    "ts": null,
    "headline": "ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program",
    "summary": "ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits (NIHB) Program for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.1",
    "url": "https://finnhub.io/api/news?id=217260305e82efabaa53c2a1f7dcdb3ddf245ab0fa0dac1d7f134b851bccb058",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742994060,
      "headline": "ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program",
      "id": 133457255,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits (NIHB) Program for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.1",
      "url": "https://finnhub.io/api/news?id=217260305e82efabaa53c2a1f7dcdb3ddf245ab0fa0dac1d7f134b851bccb058"
    }
  },
  {
    "ts": null,
    "headline": "5 Reasons To Buy Regenxbio Right Now",
    "summary": "Regenxbio Inc. is ranked a Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and major buyout potential. Click for more on RGNX stock.",
    "url": "https://finnhub.io/api/news?id=8a40b480c8d306b7e091b768b67a23d4ebda58dfb202802efbf685da9ecf8ceb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742992278,
      "headline": "5 Reasons To Buy Regenxbio Right Now",
      "id": 133458187,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1452912285/image_1452912285.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Regenxbio Inc. is ranked a Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and major buyout potential. Click for more on RGNX stock.",
      "url": "https://finnhub.io/api/news?id=8a40b480c8d306b7e091b768b67a23d4ebda58dfb202802efbf685da9ecf8ceb"
    }
  }
]